

**Advisory Committee of the
Regenerative Medicine Research Fund
Special Meeting
Wednesday, October 14, 2015**

A special meeting of the **Regenerative Medicine Research Fund Advisory Committee** (the "Committee") was held on Wednesday, October 14, 2015, at the office of Connecticut Innovations, 865 Brook Street, Rocky Hill, Connecticut.

Call to Order: Noting the presence of a quorum, Mr. Wurzer called the Advisory Committee meeting to order at 9:02 a.m.

Committee members present: David Wurzer (acting Chair); Sandra Engle, Ph.D. (by phone); Ronald Hart, Ph.D. (by phone); Mark Tomishima, Ph.D. (by phone); David Goldhamer, Ph.D. (by phone); Christopher Heinen, Ph.D. (by phone); James Hughes, Ph.D. (by phone); Kevin Rakin (by phone); Diane Krause, Ph.D. (by phone); Daniel Devine (by phone); Rosalba Sacca, Ph.D. (by phone).

Other Attendees: Margaret Cartiera, Ph.D. (CI); Ariel Drew (CI); Whitney Brown, Ph.D. (CI, by phone) Leslie Larson (CI).

Mr. Wurzer, Chief Investment Officer of Connecticut Innovations, introduced himself and stated the he was designated the acting Chair of the Advisory Committee for the special meeting.

RMRF Legislative Language Discussion

As requested by the Committee in a previous meeting, Dr. Cartiera reviewed the most recent legislative language pertaining to the Regenerative Medicine Research Fund (RMRF). Dr. Cartiera stated that the legislative documents were provided prior to the special meeting so members may review the duties and responsibilities of the RMRF Advisory Committee, and to familiarize themselves with objectives of the Fund moving forward.

Review and Finalize 2016 RFP Recommendations

Definition of "Translation"

Dr. Cartiera reiterated that a definition of translation, as set by the Committee, is to be included in the 2016 RFP. She provided the proposed definition of translational research, and invited the Committee to provide suggested revisions.

There was agreement from the Committee that the proposed definition is relevant and practical meaning of translational work. With minor grammatical revisions, as noted by the Committee, the definition will be incorporated into the 2016 RFP.

2016 RFP Recommendations

Dr. Cartiera discussed possible areas of focus for the 2016 RFP.

She provided recommendations including, specific areas of research, defined funding amounts, follow-on requests, and collaborations, etc. The recommendations sparked conversation between the Committee members as to how the RFP might meet the long-term objectives of the Fund. A lengthy discussion ensued.

The Committee members agreed that an all-day retreat in early 2016 was necessary to fully address the Fund's long-term objectives, and create a strategic plan. Until that time, there was consensus that minor revisions be made for the 2016 RFP.

Mr. Wurzer requested two motions from the Committee, approving amendments to the 2016 RFP, as recommended by the BioInnovation team.

Upon a motion made by Dr. Heinen, seconded by Dr. Sacca, the Committee members voted in favor of accepting the follow-on request recommendation language, to be incorporated into the 2016 RFP. VOTE: 9-0-0 (In favor: Heinen, Hughes, Tomishima, Sacca, Goldhamer, Devine, Hart, Engle, Krause).

Upon a motion made by Dr. Goldhamer, seconded by Dr. Hart, the Committee members voted in favor of accepting the collaboration and leverage recommendation language, to be incorporated into the 2016 RFP. VOTE: 9-0-0 (In favor: Heinen, Hughes, Tomishima, Sacca, Goldhamer, Devine, Hart, Engle, Krause).

It was requested that the RFP page limit for group project awards be decreased from 50 pages to 25 pages. There was general consensus to amend the group project application requirements to 25 pages.

Dr. Cartiera discussed next steps and the anticipated 2016 RFP release time. A discussion regarding the RMRF awardee survey, and possible next steps to increase survey participation ensued.

Next Full Advisory Committee Meeting: November 17, 2015

Adjournment:

Upon a motion made by Dr. Heinen, seconded by Dr. Hart, the Advisory Committee members voted in favor of adjourning the meeting at 10:25

Regenerative Medicine Research Fund Advisory Committee

a.m. VOTE: 9-0-0 (In favor: Heinen, Hughes, Tomishima, Sacca, Goldhamer, Devine, Hart, Engle, Krause).

Respectfully Submitted,



David Wurzer, Acting Chair
Connecticut Innovations